Celemics (A331920) Stock Overview
Designs, manufactures, and distributes sequencing kits in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A331920 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Celemics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,395.00 |
| 52 Week High | ₩5,030.00 |
| 52 Week Low | ₩2,535.00 |
| Beta | 0.77 |
| 1 Month Change | 58.95% |
| 3 Month Change | 58.66% |
| 1 Year Change | 32.38% |
| 3 Year Change | -27.48% |
| 5 Year Change | -81.02% |
| Change since IPO | -82.97% |
Recent News & Updates
Recent updates
Celemics' (KOSDAQ:331920) Shareholders Should Assess Earnings With Caution
Mar 27
Celemics (KOSDAQ:331920) Is Posting Solid Earnings, But It Is Not All Good News
Aug 26We're Not Very Worried About Celemics' (KOSDAQ:331920) Cash Burn Rate
Jul 29Here's Why We're Not Too Worried About Celemics' (KOSDAQ:331920) Cash Burn Situation
Mar 28What You Need To Know About Celemics, Inc.'s (KOSDAQ:331920) Investor Composition
Dec 17Shareholder Returns
| A331920 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 47.5% | -6.4% | -3.0% |
| 1Y | 32.4% | 1.4% | 94.4% |
Return vs Industry: A331920 exceeded the KR Life Sciences industry which returned 1.4% over the past year.
Return vs Market: A331920 underperformed the KR Market which returned 94.4% over the past year.
Price Volatility
| A331920 volatility | |
|---|---|
| A331920 Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A331920's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A331920's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 40 | Young-hoon Lee | www.celemics.com |
Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea. The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase. It also provides celemics analysis, whole exome sequencing, customized NGS panels, sequencing, bioinformatics, biopharma, and custom NGS assay development services.
Celemics, Inc. Fundamentals Summary
| A331920 fundamental statistics | |
|---|---|
| Market cap | ₩35.88b |
| Earnings (TTM) | -₩12.56b |
| Revenue (TTM) | ₩6.13b |
Is A331920 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A331920 income statement (TTM) | |
|---|---|
| Revenue | ₩6.13b |
| Cost of Revenue | ₩3.15b |
| Gross Profit | ₩2.98b |
| Other Expenses | ₩15.54b |
| Earnings | -₩12.56b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.54k |
| Gross Margin | 48.56% |
| Net Profit Margin | -204.87% |
| Debt/Equity Ratio | 0% |
How did A331920 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/09 21:59 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celemics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dong Gun Lee | Shinhan Investment Corp. |